PCSA — Processa Pharmaceuticals, Inc. catalysts
Next verified catalyst
2026-09-01 — A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breas · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metast
Phase 2 · Breast Cancer, TNBC - Triple-Negative Breast Cancer |
PCSA Processa Pharmaceuticals, In | PCS6422 and capecitabine, Capecitabine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|